Search

948 Result(s)
Sort by

empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Four Pillars Cancer Immunology

Four Pillars Cancer Immunology

Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Early careers

Early careers

At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Partnering Approach Video 2023

Partnering Approach Video 2023

Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
It Takes 2

It Takes 2

It Takes 2 people – a patient and a HCP, and 2 tests – a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
What are lay summaries

What are lay summaries

Boehringer Ingelheim produces lay summaries of clinical trials, making complex information and data from clinical studies understandable for patients and carers.
Social Support

Social Support

People living with cancer share their perspectives on the importance of social support.
China

China

Boehringer Ingelheim has been active in China since 1994. Explore career development opportunities in China or our 170 locations around the globe.
It’s Your Heart. Protect It. The Podcast.

It’s Your Heart. Protect It. The Podcast.

In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
Real stories, real impact: fighting rabies

Real stories, real impact: fighting rabies

The danger of rabies is often overlooked. The need for action, unseen. Learn how we can eliminate rabies through leveraging education and dog vaccinations.
vet scholars symposium

vet scholars symposium

Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Our Expectations

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Respimat re-usable wins Pharmapack Eco-Design Award

Respimat re-usable wins Pharmapack Eco-Design Award

The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
2019 performance

2019 performance

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
More Potential

More Potential

Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.